Lipoprotein(a) Test: What It Is, Normal Levels, and Who Should Get Tested

A lipoprotein(a) test measures a cholesterol particle that a standard lipid panel never reports. Because the particle is largely inherited, one measurement in adulthood can change how overall cardiovascular risk is read, even when LDL cholesterol looks controlled.

What Is Lipoprotein(a)?

Lipoprotein(a), shortened to Lp(a), is a cholesterol-carrying particle in the blood. Its structure resembles low-density lipoprotein, the particle behind the LDL cholesterol figure, with one important addition: a protein called apolipoprotein(a) attached to the particle surface. That added protein changes how the particle behaves in artery walls and in clotting pathways, which is why Lp(a) carries risk beyond what LDL cholesterol alone explains.¹

The defining feature of Lp(a) is how little it moves. Levels are 70 to 90 percent genetically determined, set mainly by variation in the LPA gene, which controls the size and number of apolipoprotein(a) molecules a person produces. Two people eating the same diet, with the same weight and the same LDL cholesterol, can therefore have Lp(a) levels ten or twenty times apart. That genetic stability is also what makes a single adult measurement informative for years: unlike triglycerides, which swing with recent meals, Lp(a) stays fairly steady through adult life.

Population data put the scale of the issue in plain terms. About one in five adults has an Lp(a) level at or above 50 mg/dL, the threshold treated as high in most guidance. Levels vary by ancestry as well, with higher average levels reported in people of African descent and lower average levels in some East Asian populations, a pattern that reflects the genetics of the LPA gene rather than diet or lifestyle differences between groups.¹

Elevated Lp(a) is linked with three outcomes in particular: atherosclerotic cardiovascular disease, including heart attack and ischemic stroke, and calcific aortic valve stenosis, the narrowing of the aortic valve. The European Atherosclerosis Society consensus statement describes the evidence for a causal role in atherosclerotic disease and aortic valve disease as strong, based on genetic studies, population cohorts, and laboratory work together rather than on any single study.¹

What Does an Lp(a) Test Measure?

An Lp(a) test is a blood test that measures the concentration of Lp(a) particles in a blood sample. The sample is usually drawn from a vein in the arm, and the result is reported as a single number with a unit. No imaging, no fasting preparation for the Lp(a) measurement itself, and no special procedure beyond a standard blood draw is involved.

The unit is where most confusion starts, and it deserves careful attention. Laboratories report Lp(a) in one of two units: nanomoles per liter (nmol/L), which counts particles, or milligrams per deciliter (mg/dL), which measures mass. The nmol/L unit is preferred in current guidance, because it counts particles directly and is less sensitive to the size variation between particles. The mg/dL unit measures total mass, which depends on both particle number and particle size, so two people with the same particle count can show different mg/dL values.

The practical consequence is simple and strict: the two units do not convert with a simple multiplication factor. A rough correspondence of 50 mg/dL to about 125 nmol/L appears in guidance tables, but it is an approximation, not a conversion. A result must always be read against the threshold in its own unit, and results from different laboratories or different units are not directly comparable without the assay details on the report.

Assay variation adds a second layer of caution. Different laboratory methods measure Lp(a) slightly differently, and reference ranges on a report reflect the specific assay used. That is why guidance tables give ranges with the word “about” attached, and why a borderline result is read together with the laboratory's own reference range rather than against a universal number alone.

Fasting is generally not required for a standalone Lp(a) test, because levels stay stable regardless of recent food intake. When Lp(a) is ordered as part of a full lipid panel, fasting may still be requested for the triglyceride measurement, which does change after meals. The distinction matters for anyone booking the test: the fasting instruction, when it appears, usually belongs to the panel, not to the Lp(a) measurement itself.

Lp(a) Levels Explained

The levels table below follows the thresholds used in the European Atherosclerosis Society consensus and the National Lipid Association guidance. Both use the same three bands, and both stress the same point: risk rises continuously with the level, so the bands are reference points for discussion, not cliffs where risk suddenly appears.

The continuum point is worth stating plainly, because it corrects the most common misreading of the table. A level of 130 nmol/L does not carry the same added risk as a level of 300 nmol/L, even though both sit in the “high” band. Likewise, a level of 70 nmol/L is not identical to a level of 10 nmol/L, even though both sit in the “low” band. The band gives a shorthand for discussion; the number itself, read with the rest of the risk profile, gives the fuller picture.¹

Age and sex add context but do not change the thresholds. Lp(a) levels are largely set by early adulthood and change little with age, unlike LDL cholesterol, which tends to rise with age and weight. Sex differences in average levels are small compared with the genetic variation between individuals. A high result in a younger adult therefore carries the same long-term meaning as the same result in an older adult, with more years of exposure ahead.

One more number helps place Lp(a) in a lifetime frame. Because exposure starts at birth and continues for decades, researchers describe Lp(a) risk in cumulative terms: a high level acts over a lifetime, not over a single year. That lifetime framing is why a single adult measurement, taken once, is treated as a durable piece of risk information rather than a snapshot that expires.

Who Is Lp(a) Testing Described For?

The central recommendation in current guidance is broad: measure Lp(a) at least once in adulthood. The European Atherosclerosis Society consensus statement recommends testing at least once during adult life to identify people with high cardiovascular risk, and European cardiology guidance carries the same once-in-adulthood recommendation.¹ The reasoning follows directly from the genetics: a level that barely changes does not need repeating, and a level that is never measured cannot inform risk assessment at all.

Within that broad recommendation, several groups receive particular emphasis in guidance documents, because a high result changes the discussion more for them:

• People with a family history of premature cardiovascular disease. Early heart disease in a parent or sibling, generally before age 55 in men and 65 in women, raises the prior probability of an inherited risk factor, and Lp(a) is one of the most common inherited contributors.
• People with familial hypercholesterolemia. In this inherited cholesterol condition, Lp(a) adds risk on top of already high LDL cholesterol, and measuring it refines the overall picture.
• People with recurrent events despite controlled LDL cholesterol. When heart attacks or strokes occur while LDL cholesterol is well controlled, an unmeasured Lp(a) level is one of the first explanations clinicians check, because it is the risk factor a standard panel hides.
• People with calcific aortic valve stenosis. Lp(a) is linked with aortic valve narrowing as well as artery disease, so a valve finding prompts the same measurement question.
• People at intermediate overall risk. When a standard risk estimate sits near a treatment threshold, a high Lp(a) level can tip the overall reading upward, while a low level leaves the standard estimate standing on its own.

Testing is not described as a screening program for children in routine guidance, and it is not described as a yearly check. The once-in-adulthood framing is the point: the test is cheap relative to the information it carries, it is stable, and it is currently missed in most adults because it is never ordered. Population surveys consistently find that only a small minority of adults have ever had an Lp(a) measurement, even though the recommendation for one measurement has stood for years.

How Is Lp(a) Different From LDL Cholesterol?

The confusion between Lp(a) and LDL cholesterol is understandable, because the two are related and both appear in cholesterol discussions. The table below separates them on the points that matter for reading a result.

The practical consequence shows up in clinics every day. A person can follow a heart-healthy diet, exercise regularly, and bring LDL cholesterol into a controlled range, and still carry a high Lp(a) level, because the two particles answer to different controls. That is not a failure of lifestyle effort. It is the genetics of the LPA gene operating independently of the factors that move LDL cholesterol.

The reverse also matters. A low Lp(a) level does not cancel a high LDL cholesterol level, and a controlled LDL level does not cancel a high Lp(a) level. Risk assessment adds the two together, along with blood pressure, smoking, diabetes, and family history. Readers who want the LDL side of that equation in detail can use the site's LDL cholesterol calculator, and the LDL vs HDL explainer covers the standard panel in full. For overall risk from combined factors, the AHA PREVENT calculator gives the 10-year and 30-year picture that Lp(a) then refines.

What Happens After a High Lp(a) Result?

A high Lp(a) result does not, on its own, point to a single medicine. As of 2026, medicines designed specifically to lower Lp(a) remain under study in outcome trials, and no completed outcome trial has yet shown that lowering Lp(a) itself reduces heart attacks or strokes. That fact shapes the entire clinical pathway that follows a high result, and it is important to state it plainly rather than imply a direct treatment exists.

What the pathway does focus on, in guidance after guidance, is overall cardiovascular risk. A high Lp(a) level raises the stakes for every other modifiable factor, so clinical attention turns to LDL cholesterol, blood pressure, blood sugar, smoking, and weight with greater intensity than the same profile would receive with a low Lp(a) level. In practical terms, a high Lp(a) result often moves a borderline treatment discussion into a clearer one, and it strengthens the case for tighter control of the factors that can be changed.

Statin therapy illustrates the point. Statins lower LDL cholesterol substantially and reduce cardiovascular events in people with high Lp(a) as well as in people with low Lp(a), even though statins do not lower Lp(a) itself in any meaningful way. The benefit comes from lowering the total risk burden, not from moving the Lp(a) number. The same logic applies to blood pressure control and smoking cessation: neither changes Lp(a), and both change the total risk that Lp(a) amplifies.

Two procedures appear in guidance for the highest levels, in selected settings. Lipoprotein apheresis, a blood-filtering procedure, is described for people with very high Lp(a) and progressive cardiovascular disease despite maximal risk-factor control, in centers that offer it. PCSK9 inhibitors, which lower LDL cholesterol strongly, also lower Lp(a) modestly as a secondary effect, though they are not used for Lp(a) alone. Both are specialist decisions, and neither changes the basic pathway for most people with a high result: control everything else, and control it well.

For people already taking cholesterol medicine, a high Lp(a) result also changes how LDL cholesterol is read. Standard LDL cholesterol measurements include the cholesterol carried inside Lp(a) particles, so part of a reported LDL figure in a person with high Lp(a) is Lp(a) cholesterol rather than true LDL cholesterol. Clinicians sometimes adjust for this when judging whether LDL lowering has reached its goal, a detail that matters more as Lp(a) levels rise.

Lp(a) and Family Testing

Because Lp(a) is inherited, a high result in one person carries information about relatives. The European Atherosclerosis Society consensus statement describes cascade testing, the practice of offering testing to family members after a high result is found, as part of the response to elevated Lp(a).¹ The logic is straightforward: a parent with a high level has a substantial chance of passing the genetic pattern to children, and a sibling shares the same parental genetics.

Cascade testing is described in guidance as an offer, not an obligation, and it usually starts with first-degree relatives: parents, siblings, and children. A relative who tests high gains the same lifetime information the first person gained, years earlier in life if testing happens early in adulthood. A relative who tests low gains reassurance on this one factor, though the rest of their risk profile still stands on its own.

The family angle also explains why Lp(a) testing is sometimes described as a family test rather than an individual test. Most risk factors are personal: a person's smoking, weight, or blood pressure says little about a sibling's. Lp(a) is different, because the same genetic pattern runs through families. One measurement can therefore prompt several, and the benefit multiplies across relatives in a way that a cholesterol measurement alone does not.

Limitations: What an Lp(a) Test Cannot Show

An Lp(a) test is a strong piece of risk information, and it is not a complete risk assessment. Its limits are worth stating with the same clarity as its strengths.

• It is one factor, not a verdict. A high Lp(a) level raises overall risk, but it does not predict an event for any individual, and a low level does not remove risk from smoking, diabetes, high blood pressure, or high LDL cholesterol. Risk is always read from the full profile.
• Units and assays vary. Results in nmol/L and mg/dL are not interchangeable, and different laboratory methods give slightly different numbers. A result must be read with its unit and its laboratory reference range, and borderline results deserve a second look at those details before any conclusion is drawn.
• Risk is a continuum, not a cliff. The bands in the levels table are reference points. A level just above a threshold and a level far above it carry different added risk, and a level just below a threshold is not risk-free.
• It does not measure plaque directly. Lp(a) is a blood marker of risk, not an image of arteries. Direct measurements of plaque, such as a coronary calcium scan, answer a different question, and the two are complementary rather than interchangeable.
• Levels can shift in specific settings. Although Lp(a) is stable for most adults, levels can rise in pregnancy, in kidney disease, and during acute illness or inflammation. A result drawn in one of those settings is read in that context rather than as a lifetime baseline.

None of these limits weakens the case for a once-in-adulthood measurement. They define how the result is used: as a durable, genetically set piece of the risk picture, read with its unit, its assay, and the rest of the profile, rather than as a stand-alone score.

Lp(a) Test vs Calcium Score Test

Readers often meet Lp(a) testing and calcium score testing in the same conversation, because both refine risk when standard estimates leave uncertainty. The two tests answer different questions, and the difference is worth keeping sharp.

An Lp(a) test measures a blood particle level, set by genetics, that raises risk over a lifetime. A calcium score test is a CT scan that measures calcified plaque already present in the coronary arteries, reported as a CAC score. One is a risk factor measured in blood; the other is a physical measurement of disease already present. A person can have a high Lp(a) level and a zero calcium score, because risk and established plaque are different stages of the same process, and the two results together give more information than either alone.

The same complementary logic applies to risk calculators. An AHA PREVENT calculator estimates the probability of a cardiovascular event from risk factors, and the site's ASCVD vs PREVENT comparison explains how the two leading risk models differ. Lp(a) and CAC testing both refine those probability estimates, from opposite directions: Lp(a) adds a genetic risk factor the models do not include, while CAC adds a direct measurement the models cannot see. Clinicians weigh all three pieces together, rather than letting any one override the others.

For leg circulation, a different bedside measurement answers yet another question. The site's new ABI calculator estimates the ankle-brachial index from arm and ankle pressures, for assessing blood flow to the legs. Lp(a), calcium scoring, risk calculators, and ABI testing each cover a different part of cardiovascular assessment, and none of them replaces the others.

Frequently Asked Questions